Has Nikolajs Perdue, MD received payments from drug or device companies?

Yes. Drug and device makers reported $302,261 in general payments to Nikolajs Perdue, MD across 1,234 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nikolajs Perdue, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nikolajs Perdue, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nikolajs Perdue, MD

Dermatology · Indianapolis, INNPI 1639580152

Payments from drug & device makers

$302,261in general payments, 2019–2025

Across 1,234 payments — averaging $244.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$178K
Lilly USA, LLC$51K
Sun Pharmaceutical Industries Inc.$47K
Sanofi$12K
Novartis$3K
AbbVie$2K
plus $9K from 32 others

What the payments were for

Consulting fees$10,5313%
Speaking & faculty fees$251,55783%
Travel & lodging$17,7646%
Food & beverage$22,2007%
Education$2090%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	227	$178,353
Lilly USA, LLC	140	$51,430
Sun Pharmaceutical Industries Inc.	160	$46,649
Sanofi	59	$11,593
Novartis	102	$3,026
AbbVie(2 entities)	115	$2,348
Johnson & Johnson	100	$1,787
UCB, Inc.	34	$1,046
Pfizer	68	$960
Incyte Corporation	37	$874
Galderma Laboratories, L.p.	32	$823
Regeneron Healthcare Solutions, Inc.	32	$782
LEO Pharma Inc.	29	$487
Ortho Dermatologics, A Division Of Bausch Health US, LLC	15	$329
Mayne Pharma Commercial LLC	17	$282
Arcutis Biotherapeutics, Inc.	6	$234
E.r. Squibb & Sons, L.L.C.	15	$226
Bristol Myers Squibb	2	$150
Almirall LLC	6	$100
Janssen Scientific Affairs, LLC	3	$88
Dermira, Inc.	4	$85
Dermavant Sciences, Inc.	4	$74
Boehringer Ingelheim	3	$73
VYNE Pharmaceuticals Inc.	3	$62
Journey Medical Corporation	2	$61
Aclaris Therapeutics, Inc.	3	$45
Biofrontera Inc.	2	$37
Paratek Pharmaceuticals, Inc.	2	$36
Merck	2	$33
Convatec Inc.	1	$32
Merz North America, Inc.	1	$30
Prugen, Inc. Pharmaceuticals	2	$29
Sebela Pharmaceuticals Inc.	1	$22
Verrica Pharmaceuticals Inc.	1	$19
Kyowa Kirin, Inc.	1	$17
Crossroads Orthopedics, LLC	1	$16
Mylan Pharmaceuticals Inc.	1	$13
Mission Pharmacal Company	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Otezla$172,636
ILUMYA$44,135
TALTZ$38,447
DUPIXENT$10,643
COSENTYX$1,925
Bimzelx$359
Tremfya$242
SOOLANTRA$225
AKLIEF$121
EPIDUO FORTE$121
Winlevi$117
ORACEA$104

How this compares

$302,261 in reported general payments places this provider in the 90th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana →

Medicare billing

Part B allowed, 2024

$131,924

Medicare patients

375

Services billed

1,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	60	$225,895
Clobetasol Propionate	119	$4,126
Triamcinolone Acetonide	185	$2,982
Fluorouracil	30	$2,571
Ketoconazole	129	$2,230
Doxycycline Hyclate	65	$1,346
Metronidazole	20	$934
ValacyclovirValacyclovir Hcl	13	$398
Clindamycin Phosphate	13	$362
Doxycycline Monohydrate	11	$359
Spironolactone	15	$284
Hydroxyzine Hcl	22	$277
Hydrocortisone	36	$242
Mupirocin	14	$101
Cephalexin	13	$84

Paid to pharmacies, not to this prescriber.

Other dermatology in Indianapolis

Scott FretzinIndianapolis$9.8M
David RosmarinIndianapolis$4.4M
Kenneth DawesIndianapolis$2.2M
Ginat MirowskiIndianapolis$1.8M
Christopher ObeimeIndianapolis$907K
Priya YoungIndianapolis$492K
Matthew TurnerIndianapolis$203K
Stephen WolvertonIndianapolis$29K
Annette DinneenIndianapolis$22K
Michael IsaacsIndianapolis$14K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →